Vinay Prasad will leave the FDA at the end of April, marking a second departure after a tenure marked by high-profile reversals and industry clashes. Multiple outlets reported the move; STAT and other outlets detailed controversies tied to vaccine and gene-therapy review decisions under Prasad’s leadership. The resignation follows public disputes over review pathways for Moderna’s flu shot and demands for additional trials on rare-disease therapies. The exit leaves the Center for Biologics Evaluation and Research (CBER) leadership in flux and raises immediate questions about ongoing reviews of vaccines, cell and gene therapies.